You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The SBIR grant could be worth as much as $2.3 million and will help PapGene develop and commercialize its proprietary ovarian and endometrial cancer detection test.
The firm will use the award to develop silica nanomaterial for use with many sample types, including blood, cultured cells, and pathogens.
The company believes it can make oligonucleotide synthesis faster and cheaper than currently available methods, and plans to launch a platform in the next year.
The company is developing a cloud-based platform for the detection, quantification, and interpretation of alternative splicing variation from NGS data.
The technology will allow scientists or clinicians to load crude blood sample and generate DNA sequencing libraries in a fully automated workflow.
The company is developing multiplexed and reverse-phase array versions of its protein phosphorylation-detection technology.
The company aims to use the funding to further optimize the technology and support an ongoing early-access program with beta testers.
The company said the library will be made freely available to academic and non-profit investigators through the DECIPHER Project.
The company aims to launch the qPCR-based test in sub-Saharan Africa.
The products will initially be commercialized for research applications, but the firm hopes to move into diagnostics down the road.
Researchers have developed a robotic lab assistant, the Verge reports.
CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.
The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.
In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.